Tags

Type your tag names separated by a space and hit enter

The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
Ann Chir Gynaecol. 1994; 83(4):316-9.AC

Abstract

Although osteosclerotic metastases are characteristic of prostate cancer, bone resorption is also accelerated. Clodronate is a specific inhibitor of osteoclastic bone resorption and relieves bone pain of osteolytic lesions in myelomatosis and breast cancer. The present open study included 16 prostate cancer patients who had painful bone metastases and who had failed hormonal therapy. Clodronate was given intravenously for six days (300 mg/day) followed by oral treatment for 21 days (3200 mg/day). A clear pain relief was found in nine of the 16 (56%) patients after intravenous administration. During the next three weeks with oral administration there was still pain reduction in five patients, while in three patients the pain increased. The treatment had no effect on conventional tumour markers but urinary hydroxyproline excretion decreased, indicating reduced bone resorption. Clodronate offers an alternative for treating patients with painful metastases from prostate cancer.

Authors+Show Affiliations

Department of Surgery, Tampere University Hospital, Finland.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7537482

Citation

Kylmälä, T, et al. "The Effect of Combined Intravenous and Oral Clodronate Treatment On Bone Pain in Patients With Metastatic Prostate Cancer." Annales Chirurgiae Et Gynaecologiae, vol. 83, no. 4, 1994, pp. 316-9.
Kylmälä T, Tammela TL, Lindholm TS, et al. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chir Gynaecol. 1994;83(4):316-9.
Kylmälä, T., Tammela, T. L., Lindholm, T. S., & Seppänen, J. (1994). The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Annales Chirurgiae Et Gynaecologiae, 83(4), 316-9.
Kylmälä T, et al. The Effect of Combined Intravenous and Oral Clodronate Treatment On Bone Pain in Patients With Metastatic Prostate Cancer. Ann Chir Gynaecol. 1994;83(4):316-9. PubMed PMID: 7537482.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. AU - Kylmälä,T, AU - Tammela,T L, AU - Lindholm,T S, AU - Seppänen,J, PY - 1994/1/1/pubmed PY - 1994/1/1/medline PY - 1994/1/1/entrez SP - 316 EP - 9 JF - Annales chirurgiae et gynaecologiae JO - Ann Chir Gynaecol VL - 83 IS - 4 N2 - Although osteosclerotic metastases are characteristic of prostate cancer, bone resorption is also accelerated. Clodronate is a specific inhibitor of osteoclastic bone resorption and relieves bone pain of osteolytic lesions in myelomatosis and breast cancer. The present open study included 16 prostate cancer patients who had painful bone metastases and who had failed hormonal therapy. Clodronate was given intravenously for six days (300 mg/day) followed by oral treatment for 21 days (3200 mg/day). A clear pain relief was found in nine of the 16 (56%) patients after intravenous administration. During the next three weeks with oral administration there was still pain reduction in five patients, while in three patients the pain increased. The treatment had no effect on conventional tumour markers but urinary hydroxyproline excretion decreased, indicating reduced bone resorption. Clodronate offers an alternative for treating patients with painful metastases from prostate cancer. SN - 0355-9521 UR - https://www.unboundmedicine.com/medline/citation/7537482/The_effect_of_combined_intravenous_and_oral_clodronate_treatment_on_bone_pain_in_patients_with_metastatic_prostate_cancer_ DB - PRIME DP - Unbound Medicine ER -